Graduate Institutes of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Hepatology. 2018 Feb;67(2):586-599. doi: 10.1002/hep.29328. Epub 2017 Dec 26.
Several strategies to improve the efficacy of radiation therapy against hepatocellular carcinoma (HCC) have been investigated. One approach is to develop radiosensitizing compounds. Because histone deacetylase 4 (HDAC4) is highly expressed in liver cancer and known to regulate oncogenesis through chromatin structure remodeling and controlling protein access to DNA, we postulated that HDAC4 inhibition might enhance radiation's effect on HCC cells. HCC cell lines (Huh7 and PLC5) and an ectopic xenograft were pretreated with HDAC inhibitor or short hairpin RNA to knock down expression of HDAC4 and then irradiated (2.5-10.0 Gy). We evaluated cell survival by a clonogenic assay; apoptosis by Annexin V immunofluorescence; γH2AX, Rad51, and HDAC4 by immunofluorescence staining; HDAC4, Rad51, and ubiquitin-conjugating enzyme 9 (Ubc9) in HCC cell nuclei by cell fractionation and confocal microscopy; physical interaction between HDAC4/Rad51/Ubc9 by immunoprecipitation; and the downstream targets of HDAC4 knockdown by immunoblotting. Both HDAC4 knockdown and HDAC inhibitor enhanced radiation-induced cell death and reduced homologous recombination repair of DNA double-strand breaks and protein kinase B activation, leading to increased apoptosis. HDAC4 knockdown with or without an HDAC inhibitor significantly delayed tumor growth in a radiation-treated xenograft model. Radiation stimulated nuclear translocation of Rad51 in an HDAC4-dependent manner and the binding of Ubc9 directly to HDAC4, which led to Ubc9 acetylation. Moreover, these effects were accompanied by HDAC4/Ubc9/Rad51 complex dissociation through inhibiting nuclear translocation. Conclusion: HDAC4 signaling blockade enhances radiation-induced lethality in HCC cells and xenografts. These findings raise the possibility that HDAC4/Ubc9/Rad51 complex in DNA repair may be a target for radiosensitization of HCC. (Hepatology 2018;67:586-599).
已经研究了几种提高放射疗法治疗肝细胞癌 (HCC) 疗效的策略。一种方法是开发放射增敏化合物。由于组蛋白去乙酰化酶 4 (HDAC4) 在肝癌中高度表达,并且已知通过染色质结构重塑和控制蛋白质与 DNA 的接触来调节肿瘤发生,我们推测 HDAC4 抑制可能增强辐射对 HCC 细胞的作用。用 HDAC 抑制剂或短发夹 RNA 预处理 HCC 细胞系 (Huh7 和 PLC5) 和异位异种移植物,以敲低 HDAC4 的表达,然后进行照射 (2.5-10.0 Gy)。我们通过集落形成试验评估细胞存活率;通过 Annexin V 免疫荧光评估细胞凋亡;通过免疫荧光染色评估 γH2AX、Rad51 和 HDAC4;通过细胞分离和共聚焦显微镜评估 HCC 细胞核中的 HDAC4、Rad51 和泛素连接酶 9 (Ubc9);通过免疫沉淀评估 HDAC4/Rad51/Ubc9 之间的物理相互作用;通过免疫印迹评估 HDAC4 敲低的下游靶点。HDAC4 敲低和 HDAC 抑制剂均增强了辐射诱导的细胞死亡,减少了 DNA 双链断裂的同源重组修复和蛋白激酶 B 的激活,从而增加了细胞凋亡。在辐射治疗的异种移植模型中,HDAC4 敲低联合或不联合 HDAC 抑制剂显著延迟了肿瘤生长。辐射以 HDAC4 依赖性方式刺激 Rad51 的核易位,并直接使 Ubc9 与 HDAC4 结合,导致 Ubc9 乙酰化。此外,这些作用伴随着通过抑制核易位导致 HDAC4/Ubc9/Rad51 复合物解离。结论:HDAC4 信号通路阻断增强了 HCC 细胞和异种移植物中辐射诱导的致死性。这些发现提示 DNA 修复中的 HDAC4/Ubc9/Rad51 复合物可能是 HCC 放射增敏的靶点。(《肝脏病学》2018 年;67:586-599)